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- Adverse effects
-  Prescribing within clinical trials and availability of unlicensed medi-
cines
- License extension
Conclusion: This investigation found variation between actual 
uptake of new medicines and the predictions provided in Forward 
Look reports and SMC advice. The 7 factors identified assist in 
explaining the variations observed, are useful in understanding the 
challenges in making accurate predictions, and provide some areas 
in which action could be taken to further develop and potentially 
improve predictions in Forward Look reports and SMC advice.
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Introduction: Drug manufacturers developed “evergreening strate-
gies” to compete with generic medication after patent termination. 
These include marketing of slightly modified follow-on drugs. We 
identified 8 follow-on drugs available in the canton of Geneva during 
the study period: 3 drugs for which an isomer had been marketed 
(levocetirizine as follow-on drug of cetirizine; escitalopram/citalo-
pram; esomeprazole/omeprazole); 1 active metabolite (desloratidine 
– loratidine); 2 combination formulations of the originally patented 
drug (alendronic acid alone – alendronic acid combined with colecal-
ciferol; simvastatin alone – simvastatin with ezetimib); 1 slow-release 
formulation (zolpidem extended release); and 1 structural analogue 
(pregabaline – gabapentine). We aimed to estimate the financial 
impact of these drugs on overall health care costs.
Patients (or Materials) and Methods: The impact of evergreening 
strategies on health care spending was analyzed in the community 
database that includes > 73% of the total of insured patients. Costs 
were analyzed under 3 scenarios, assuming a replacement with the 
corresponding generic when available of: (1) all brand drug prescrip-
tions; (2) all follow-on; and (3) both follow-on and brand prescrip-
tions. The “extra-cost” was assessed by the difference between the 
total cost based on the observed data and the total cost estimated in 
the 3 scenarios.
Results: Based on our scenario 1 (no brand) and 2 (no follow-on) of 
“extra-costs,” the health care system could have saved over the entire 
study period € 15.9 (95% CI, 15.5–16.2) million and € 14.4 (95% CI, 
14.1–14.7) million if brand or follow-on drug prescriptions, respec-
tively, had replaced. This amounted to € 30.3 (95% CI, 29.8–30.8) 
million over the entire study period if brand and follow-on drug pre-
scriptions were replaced at their corresponding community generic 
selling price equivalents when available (scenario 3).
Conclusion: Evergreening strategies have been successful in maintain-
ing market share in Geneva, offsetting competition by generics and 
cost-containment policies. Therefore, health care providers and policy 
makers should be aware of the impact of evergreening strategies.
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Introduction: Intravenously administered Busulfan (Bu) in children 
undergoing hematopoietic stem cell transplantation (HSCT) exhibits 
therapeutic window phenomenon requiring therapeutic drug moni-
toring. The dosage of Bu is adjusted based on the first dose phar-
macokinetic parameters. Existing methods for the analysis of Bu 
require long turnaround times with relatively large amounts of blood 
collection for plasma separation.
Objective: To evaluate the utility of dried blood sampling (DBS) 
and dried plasma sampling (DPS) using only 5 μ L of whole blood or 
plasma for therapeutic monitoring of Bu levels.
Patients (or Materials) and Methods: Venous blood samples were 
collected from 2 children after the infusion of Bu at doses1, 2, 3, 5, 
and 9 (n = 34). Then, 5 μ L each of whole blood and plasma were 
spotted onto Whatman 903 DBS cards and dried at room tempera-
ture for 30 minutes. The entire spots were cut and then analyzed by 
a validated LC-MS/MS method. Bu was also measured by established 
gas chromatography coupled to mass spectrometry (GC-MS) method 
using plasma (n = 13) to compare both the methods.
Results: A good correlation was observed between the levels meas-
ured by DBS and DPS (r2 = 0.95; slope = 0.84). The Bu levels meas-
ured by DPS (r2 = 0.92; slope = 0.95) and DBS (r2 = 0.91; slope = 
0. 80) were correlated with those measured by GC-MS method. The 
levels estimated by DBS were less than those obtained by DPS and 
GC-MS methods. The hematocrit (Hct) values of 2 children were in 
the range of 25.6% to 30.3%, indicating the direct influence of Hct 
on the measured Bu levels measured by DBS sampling. Therefore, 
these 2 sampling methods can be used interchangeably with due con-
sideration of the Hct value when whole blood sample is used. The 
plasma levels can be obtained from DBS levels using the formula 
“Plasma levels (analyte) = DBS levels analyte/ (1 – hematocrit).” The 
plasma levels of Bu estimated using this formula were higher than 
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those obtained by DPS or GC-MS levels, suggesting that a fraction 
of Bu binds to blood cells.
Conclusion: This novel method can be applied with only 5 μ L of 
whole blood for routine therapeutic drug monitoring of Bu with 
accuracy and faster turnaround times in HSCT. Possibility of using 
capillary blood for dried blood sampling is under evaluation for its 
feasibility and accuracy to monitor Bu levels in pediatric patients.
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Introduction: Imatinib trough plasma concentrations (Cmin) have 
been correlated with treatment response in chronic myeloid leukemia 
(CML) patients. The use of Cmin monitoring for optimizing imatinib 
dosage (therapeutic drug monitoring [TDM]) is therefore proposed 
for patients with unsatisfying response or tolerance (“rescue TDM”). 
A cycle of “routine TDM” for dosage individualization could also 
be beneficial to prevent unfavorable events, yet its clinical usefulness 
has not been evaluated. We aimed to assess prospectively whether 
a “routine TDM” intervention targeting imatinib Cmin of 1000 ng/mL 
(tolerance, 750–1500 ng/mL) could improve efficacy, tolerance, and 
persistence on treatment compared with “rescue TDM” use only.
Patients (or Materials) and Methods: The Swiss Imatinib 
COncentration Monitoring Evaluation (I-COME) study was a multi-
center randomized controlled trial (ISRCTN31181395). Adult patients 
in chronic or accelerated phase CML receiving imatinib ≤5 years were 
eligible. Patients were randomly (1:1) allocated to receive “routine 
TDM” intervention or to serve as controls with access only to “res-
cue TDM”. All had 1-year follow-up. The primary endpoint was a 
combined efficacy-safety outcome (failure- and toxicity-free survival 
without imatinib discontinuation), analyzed in intention-to-treat.
Results: Among 56 CML recruited patients, 55 had their molecular 
and cytogenetic response measured. 14/27 of patients receiving “rou-
tine TDM” (52% [33%–71%]) remained event-free versus 16/28 of 
control patients with “rescue TDM” only (57% [39%–75%]; P = 
0.69). In the “routine TDM” group, dosage recommendations were 
adopted entirely in 50% of patients (median Cmin at study end, 895 
ng/mL; CV = 33%). These patients had fewer unfavorable events 
(28% [5%–52%]) compared with patients not receiving the advised 
dosage (77% [54%–99%]; P = 0.03; median Cmin at study end, 648 
ng/mL; CV = 38%).
Conclusion: This first prospective target concentration intervention 
trial could not formally demonstrate a benefit of “routine TDM” 
of imatinib, especially due to a small patient number and limited 
prescriber’s adherence to dosage recommendations. Nevertheless, 
the patients receiving the advised dosage more often met target 
concentrations and the combined outcome (efficacy, tolerance, and 
persistence). A cycle of routine TDM could thus be favorable, at 
least in patients eligible for dosage adjustment. Its usefulness should, 
however, be further confirmed in larger trials.
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Introduction: Ponesimod is a selective sphingosine-1 phosphate 
(S1P1) receptor modulator currently in clinical development for 
multiple sclerosis and plaque psoriasis. The aim of this study was 
to assess the maximum tolerated dose of increasing multiple doses 
(3-day titration steps) of ponesimod in healthy subjects.
Patients (or Materials) and Methods: This was a single-center, dou-
ble-blind, placebo-controlled, randomized, parallel-group, up-titra-
tion study in healthy male and female subjects (n = 16). The subjects 
received ascending oral doses either of ponesimod (n = 12) or placebo 
(n = 4) once daily for 3 days at each dose level (10 mg, 20 mg, 40 
mg, 60 mg, 80 mg, 100 mg). The pharmacodynamics of ponesimod 
were assessed by measuring the total lymphocyte count. The safety 
and tolerability was evaluated by monitoring adverse events, assess-
ing standard blood chemistry and hematology laboratory variables, 
12-lead ECG recordings and telemetry, measuring of vital signs, and 
pulmonary function tests (PFTs).
Results: A plateau in mean lymphocyte count reduction from base-
line of ~70% was reached at the 40-mg dose level. The most frequent 
adverse events, all of mild to moderate intensity, were chest discom-
fort (experienced by 58% of subjects), headache (50%), dizziness 
(42%), dyspnea (42%), abdominal pain (33%), and night sweats 
(25%). A transient decrease in heart rate was observed after adminis-
tration of the first 10-mg ponesimod dose (–9 bearts/min at 1.5 hours 
postdose [placebo, –2 beats/min]). After up-titration from 10 to 20 
mg (–7 beats/min at 1.5 hours postdose [placebo, –5 beats/min]) and 
following up-titration to higher doses, the decrease in heart rate with 
ponesimod was similar to placebo, suggesting that desensitization to 
the heart rate effect had occurred. A dose-dependent decrease in PFTs 
was observed and reached a plateau with 60-mg ponesimod (maximal 
mean decrease of 1.24 L [–30.5%] in forced expiratory volume in 1 
second [FEV1] and 0.70 L [–13.7%] in forced vital capacity [FVC]). 
At the dose levels of 80 to 100 mg, several subjects reported chest 
discomfort and dyspnea. The effects on heart rate, lymphocytes, and 
PFTs were fully reversible and reached baseline values within 10 days 
after discontinuation of treatment.
Conclusion: Ponesimod was tolerated by subjects exposed to doses 
of 10 to 100 mg during the 18-day up-titration regimen. The maxi-
